Logo
Sponsored by:

Presented by:

Screening for drug candidates that improve outcomes in cancer immunotherapy

Thursday, October 10, 2019,
8AM PDT | 11AM EDT | 4PM BST | 5PM CEST 

Your details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

  Register

Overview

Screening for drug candidates that improve outcomes in cancer immunotherapy

Thursday, October 10, 2019,
8AM PDT | 11AM EDT | 4PM BST | 5PM CEST

If you've already registered, please click here to log in to the webcast.

In recent years, immunotherapy has become the most innovative and promising way to treat cancer by overcoming its hallmark of immune evasion. This approach targets modulation of the immune checkpoints that control antitumor T-cell responses by releasing the brakes on antitumor T cells. Current therapies focus on CTLA-4 and PD-1 surface receptors, with very promising results, but also with serious side effects. The limitations of these therapies and others tried so far (CAR T cells, dendritic cells, etc.) call for novel ways to improve their outcome. One approach is to induce the infiltration, activation, and expansion of CD8+ T cells in the tumor microenvironment (TME) by locally stimulating the innate immune response via secretion of IFNs and other cytokines.

This webinar will showcase efforts to find potential drug candidates that modulate the innate immune response utilizing fragment-based screening. The speakers will share results from screening campaigns using two biophysical methods for molecular interaction screening: MicroScale Thermophoresis (MST) and Temperature Related Intensity Change (TRIC), as well as a library of 2,600 fragments. They will also present preliminary results from ongoing crystallographic hit characterization and in silico hit optimization.

 During this webcast you will learn about:

  • How understanding new ways to stimulate the innate immune response in the TME is advancing the field of cancer immunotherapy
  • How fragment-based screening is helping researchers find potential drug candidates (agonists) that modulate these pathways by interacting with adaptor molecules
  • Other methods used to characterize and optimize hits
This webcast has been produced for NanoTemper Technologies by Nature Research Custom Media. The sponsor, NanoTemper Technologies, retains sole responsibility for content. About this content.

Presenters

Presenter
Dr. Ismail Moarefi
CEO
Crelux
View Biography
Presenter
Dr. Amit J. Gupta
Product Manager
NanoTemper Technologies
View Biography
Presenter
Dr. Jayshan Carpen
Moderator
Nature Research
View Biography